Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Form 144 Notice for Sera Prognostics, Inc. (SERA) discloses a proposed sale of 2,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $6,340.00, scheduled approximately for 09/09/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 02/06/2024 and fully paid on that date. The filing also reports three share dispositions by the same person in the past three months: 6,000 shares on 08/20/2025 (gross proceeds $13,290.00), 5,962 shares on 08/08/2025 (gross proceeds $15,143.48), and 667 shares on 06/10/2025 (gross proceeds $987.16). Several filer and issuer contact fields in the notice are blank in the provided text.
Sera Prognostics filed a Form 144 reporting a proposed sale of 3,899 common shares on the NASDAQ through Morgan Stanley Smith Barney, with an aggregate market value of $12,359.83 and total shares outstanding of 37,094,109.
The filing shows the shares were acquired as Restricted Stock Units from the issuer on 07/05/2025 and the approximate sale date is 09/09/2025. The filer states there were no sales of the issuer's securities by the same person in the past three months and affirms no undisclosed material adverse information.
Sera Prognostics, Inc. reporting persons Whetstone Capital Advisors, LLC and David Atterbury disclosed beneficial ownership of 3,632,371 shares of Class A common stock, equal to 9.9% of the class as of the required reporting date. The filing shows no sole voting or dispositive power; all voting and dispositive power is shared.
The Schedule 13G states the shares are not held to change or influence control of the issuer. The reporting address and CUSIP are provided, and the statement is signed by Mr. Atterbury as Manager and CCO/President.
Mirza Mansoor Raza, a director of Sera Prognostics, Inc. (SERA), reported a non-discretionary sale of 222 shares of Class A common stock on 09/05/2025 to satisfy tax withholding from vested restricted stock units. The shares were sold via a mandated "sell-to-cover" process at a weighted average price of $3.35 (transactions ranged $3.35–$3.36). After the transaction the reporting person beneficially owned 58,480 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact.
Form 144 notice (SERA) records a proposed sale of 222 Class A common shares through Morgan Stanley Smith Barney on 09/05/2025 with an aggregate market value of 744. The filing states these shares were acquired the same day via restricted stock unit vesting and lists total shares outstanding as 38,061,868. The filer disclosed three sales in the past three months by Mansoor Raza Mirza: 107 shares on 06/06/2025 for gross proceeds 169; 234 shares on 07/07/2025 for gross proceeds 552; and 225 shares on 08/05/2025 for gross proceeds 563. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Sera Prognostics insider sale by Chief Data Officer — The reporting person, Paul Kearney, executed a sale of 1,458 shares of Class A common stock on 09/02/2025 at a reported price of $3.49 per share. After the sale, the filing shows the reporting person beneficially owns 176,940 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025, and the Form 4 was submitted by an attorney-in-fact.
Sera Prognostics, Inc. (SERA) Form 144 notice reports a proposed sale of 1,458 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The filing shows an aggregate market value of $4,709.34 for the proposed sale and lists 37,094,109 shares outstanding. The shares to be sold were acquired as restricted stock units on 05/15/2024. The filer also reported three recent sales during the past three months by the same person totaling 18,313 shares for gross proceeds of $55,139.26 on 06/10/2025, 08/08/2025, and 08/29/2025.
Sera Prognostics insider sale reported. Paul Kearney, Chief Data Officer, filed a Form 4 disclosing a sale of 10,542 shares of Class A common stock on 08/29/2025 at a reported price of $3.49 per share. After the transaction Mr. Kearney beneficially owned 178,398 shares, held directly. The filing states the trade was executed under a Rule 10b5-1 trading plan adopted May 21, 2025, indicating the sale was preplanned rather than a discretionary transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.
Sera Prognostics (SERA) Form 144 notice reports a proposed sale of 10,542 common shares with an aggregate market value of $32,469.36 through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 08/29/2025.
The shares were acquired as restricted stock units from the issuer on 02/06/2024. The filer also reported recent disposals in the past three months: 6,460 shares sold on 08/08/2025 for $16,408.40 and 1,311 shares sold on 06/10/2025 for $1,940.28. The filer certifies no undisclosed material adverse information and includes standard Notice and signature statements.
Harrison Robert Gardner, Chief Information Officer of Sera Prognostics, Inc. (SERA), reported a sale of 6,000 shares of Class A common stock on 08/20/2025 under a pre-existing Rule 10b5-1 trading plan adopted May 21, 2025. The shares were sold at a weighted average price of $2.22, with executed prices ranging from $2.17 to $2.25. After the sales, the reporting person beneficially owned 102,577 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on the same date.